Uploaded October 2026 | Updated November 2026, 1 day ago
How can a virus help deliver a healthy gene to a diseased cell—and why is AAV central to many gene therapy approaches? In this video, you’ll learn how adeno-associated virus (AAV) became a promising delivery vehicle and how Bayer and AskBio are working together to advance genomic medicine.
Dr. Richard Jude Samulski, scientific founder of AskBio, was the first to clone AAV for therapeutic purposes. Because AAV is not known to cause disease in humans, it can be engineered to deliver genetic instructions to cells affected by certain single-gene conditions—an approach with potential across many genetic diseases.
In this video, you’ll learn:
- What AAV is and why it’s used in gene therapy research
- How viral vectors are designed to deliver genes to target cells
- How AskBio was founded by scientists alongside parents of children with genetic diseases
- How Bayer’s capabilities in cardiovascular disease, clinical translation, and market access complement AskBio’s expertise in molecular biology and viral vector design
- How advances across cell therapy, gene therapy, and gene editing may help accelerate progress
Bayer and AskBio are focused on improving viral delivery systems and translating research into potential new therapies for patients.
This video is for general informational purposes only and does not provide medical advice.
How can a virus help deliver a healthy gene to a diseased cell—and why is AAV central to many gene therapy approaches? In this video, you’ll learn how adeno-associated virus (AAV) became a promising delivery vehicle and how Bayer and AskBio are working together to advance genomic medicine.
Dr. Richard Jude Samulski, scientific founder of AskBio, was the first to clone AAV for therapeutic purposes. Because AAV is not known to cause disease in humans, it can be engineered to deliver genetic instructions to cells affected by certain single-gene conditions—an approach with potential across many genetic diseases.
In this video, you’ll learn:
- What AAV is and why it’s used in gene therapy research
- How viral vectors are designed to deliver genes to target cells
- How AskBio was founded by scientists alongside parents of children with genetic diseases
- How Bayer’s capabilities in cardiovascular disease, clinical translation, and market access complement AskBio’s expertise in molecular biology and viral vector design
- How advances across cell therapy, gene therapy, and gene editing may help accelerate progress
Bayer and AskBio are focused on improving viral delivery systems and translating research into potential new therapies for patients.
This video is for general informational purposes only and does not provide medical advice.










